| Name | Title | Contact Details |
|---|
Saint Peters Healthcare System, Inc. is a New Jersey nonprofit corporation sponsored by the Roman Catholic Diocese of Metuchen. The System consists of Saint Peters University Hospital, Saint Peters Health & Management Services Corporation and The Saint Peters Foundation. Saint Peters Healthcare System was formed in 2007 and reflects the expansive scope of health and wellness services we offer to our community. Our services are offered to all. We are a Catholic institution with a capital C and a small c. We draw inspiration from our religious heritage. Our care for others is universal, extending to those of other faiths and in some cases, of no faith whatsoever. Without question, the fact that ours is a faith-based healthcare delivery system is of primary significance. At Saint Peters Healthcare System, you will find leading-edge technology and an experienced staff. You will also find the trust and compassion that we have always been known for.
CollaborateMD was founded in 1999 to help medical practices and medical billing services thrive in the jungle of ever changing government and insurance payer regulations without having to spend a fortune on software, support, and hardware.
Teresian House is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Longmont United Hospital we are committed to providing compassionate health care in a healing environment and to providing leadership to improve the health of the community we serve. We are a full-service, 201-bed, non-profit hospital. Our specialty areas include Women’s Services, Orthopedics, Cardiology, Oncology, Robotic Surgery, Transitional Care and Acute Medical Services. Our 24-hour Emergency Department is a Level III Trauma Center. Longmont United Hospital is a Planetree Patient-Centered Care Designated hospital in Northern Colorado. We have served the people of Longmont, CO for over 59 years.
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.